MJMax Jacobs

Max Jacobs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Max Jacobs has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

    by Joseph M. Rocco, Joseph H. Oved, Rikita J. Patel, A. Zara Herskovits, Namitha Nair, Bita Shakoory, Thomas E. Robertson, Rachel Dileo, Max W. Jacobs, Christa S. Zerbe, et al.

    Hemophagocytic lymphohistiocytosis (HLH) is an interferon gamma–driven hyperinflammatory syndrome with high morbidity and mortality. Identifying reliable prognostic biomarkers is challenging due to various predisposing conditions and triggers. C-X-C-motif ligand 9 (CXCL9) is a clinically validated biomarker and surrogate marker of interferon gamma–mediated inflammation. We aimed to identify the role of CXCL9 in predicting severe disease and death in adults with HLH using a multicenter retrospective cohort of consecutively hospitalized patients who underwent a clinical evaluation for HLH that included CXCL9 testing. Patients were classified as HLH if they met HLH-2004 and/or HScore criteria. Conditional inference decision trees and Cox regression models were used to identify which clinical variables associated with acute mortality in patients with HLH. Overall, 171 patients were reviewed, and 126 patients met HLH criteria. The median age was 55 years (interquartile range, 40-66), with 62% male and 51% White. CXCL9 was markedly elevated in patients with HLH. Unbiased decision tree modeling, incorporating all clinical laboratory values, identified only CXCL9 of >16 100 pg/mL as the optimal predictor of inpatient mortality. Cox regression models demonstrated that CXCL9 of >16 100 pg/mL was significantly associated with 90-day mortality when controlling for important covariates. This shorter time to death in the elevated CXCL9 subgroup remained significant even after subdividing patients into those with malignancy (n = 53) and nonmalignancy HLH (n = 73). Continuous increases in CXCL9 within the cohort strongly associated with greater mortality. CXCL9 is a novel clinical marker that identifies high-risk HLH independent of underlying disease and could be used to select patients for early and aggressive targeted immunomodulatory therapy.


  • Open Access

    Feasibility and Potential Clinical Ramifications of Using Bacteriophage Therapy for S. aureus Necrotizing Fasciitis

    by James B. Doub, Dakarai Dunbar, Sara Jain, Maggie Manchester, Lila Berle, Janvi Madhiwala, Bradley Anderson, Riva Malick, Max Jacobs, Kenneth L. Urish

    Background: Staphylococcus aureus necrotizing fasciitis is a life-threatening infection requiring aggressive surgical and medical management. Despite these interventions, tremendous morbidity and mortality occur. Thus, novel agents are needed to reduce these negative outcomes. Consequently, the aims of this translational study were to evaluate the feasibility of using bacteriophages and the potential clinical ramifications of using bacteriophages in treatment of S. aureus necrotizing fasciitis. Methods: Necrotizing fasciitis clinical isolates (n = 6) were tested against different Staphylococcal bacteriophages (n = 4) to assess for activity. After exposure to bacteriophages that had growth inhibition for more than 16 h, the ability of S. aureus to change phenotypic expression of numerous enzymes was evaluated, and the ability to reduce bacterial virulence was measured with the Caenorhabditis elegans assay. Results: Staphylococcal myoviridae bacteriophages were able to lyse most clinical isolates (83%). Interestingly, after exposure to myoviridae bacteriophages, S. aureus isolates had no expression of hemolysin, secreted coagulase, or lecthinase, or the ability to ferment mannitol. These same bacteriophages also caused statistically significant decreases in bacterial virulence (p < 0.05). Neither findings were observed for bacteriophages of the podoviridae family. Conclusions: To use bacteriophages for S. aureus necrotizing fasciitis, cocktails of Staphylococcal myoviridae are likely needed to allow for broad host ranges, mitigating the need for in vitro sensitivity testing. Moreover, Staphylococcal myoviridae have the potential to reduce specific enzyme expression and global virulence of residual S. aureus. Thus, bacteriophages may aid in reducing necrotizing fasciitis morbidity by not only lysing S. aureus but also by reducing S. aureus virulence.


  • Open Access

    Performance of α-Defensins in Diagnosing Nosocomial Ventriculitis

    by Max W Jacobs, James B Doub

    Nosocomial ventriculitis can be an extremely difficult infectious disease process to diagnose, thereby exposing patients to increased morbidity and unwarranted aggressive antibiotics. Thus, novel ventriculitis diagnostics are drastically needed. In this study, we demonstrate excellent sensitivity and specificity of cerebral spinal fluid α-defensins to aid in diagnosing ventriculitis.

  • Open Access

    Babesiosis with low parasitemia as a cause of secondary hemophagocytic lymphohistiocytosis in a previously healthy adult

    by Max W. Jacobs, Joseph M. Rocco, Lisa K. Andersen, Thomas E. Robertson


  • Open Access

    A Unique Case Report of Leclercia adecarboxylata Causing Monomicrobial Neurosurgical Infections

    by Madeleine Purcell, Max Jacobs, Nazary Nebeluk, James B. Doub

    Leclercia adecarboxylata is an emerging gram‐negative pathogen. Historically, it has primarily affected immunocompromised individuals and has mainly been isolated from polymicrobial infections. Yet, advances in diagnostic techniques have led to increased recognition of its incidence and clinical relevance. In this case series, two instances of monomicrobial L. adecarboxylata infections following neurosurgical procedures in immunocompetent patients are presented. The first case occurred after spinal laminectomy, and the other case caused external ventricular drain ventriculitis. Both patients responded well to targeted antibiotic therapy, with no sequela or recurrence of infection. These cases represent the first documented neurosurgical infections caused by L. adecarboxylata , highlighting the organism’s potential as a nosocomial pathogen and underscoring the need for heightened clinical awareness and further investigation into its epidemiology to prevent further infections.


  • Open Access

    Anti-PF4 ELISA-Negative, SRA-Positive Heparin-Induced Thrombocytopenia

    by Abraham Attah, Chelsea Peterson, Max Jacobs, Rama Bhagavatula, Deep Shah, Robert Kaplan, Yazan Samhouri

    Heparin products are frequently used in the inpatient setting to prevent and treat venous thromboembolism, but they simultaneously put patients at risk of developing heparin-induced thrombocytopenia (HIT). The 4Ts score determines the pretest probability of HIT. Diagnosis is made with a screening antiplatelet factor (PF4) immunoassay and the serotonin-release assay (SRA) as a confirmatory test. Anti-PF4 assays have high sensitivity (98%) but lower specificity (50%) and result in frequent false-positive tests. We present a rare case from our institution of a patient with anti-PF4–Polyanion ELISA-negative, SRA-positive HIT and describe the challenges in making a timely diagnosis in this case.


  • Open Access

    Analysis of a beta-lactam allergy assessment protocol challenging diverse reported allergies managed by an antimicrobial stewardship program

    by Max W. Jacobs, Derek N. Bremmer, Nathan R. Shively, Matthew A. Moffa, Tamara L. Trienski, Dustin R. Carr, Carley A. Buchanan, Thomas L. Walsh

    Objective:To assess the safety and efficacy of a novel beta-lactam allergy assessment algorithm managed by an antimicrobial stewardship program (ASP) team.Design:Retrospective analysis.Setting:One quaternary referral teaching hospital and one tertiary care teaching hospital in a large western Pennsylvania health network.Patients or participants:Patients who received a beta-lactam challenge dose under the beta-lactam allergy assessment algorithm.Interventions:A beta-lactam allergy assessment protocol was designed and implemented by an ASP team. The protocol risk stratified patients’ reported allergies to identify patients appropriate for a challenge with a beta-lactam antibiotic. This retrospective analysis assessed the safety and efficacy of this protocol among patients receiving a challenge dose from November 2017 to July 2021.Results:Over a 45-month period, 119 total patients with either penicillin or cephalosporin allergies entered the protocol. Following a challenge dose, 106 (89.1%) patients were treated with a beta-lactam. Eleven patients had adverse reactions to a challenge dose, one of which required escalation of care to the intensive care unit. Of the patients with an unknown or low-risk reported allergy, 7/66 (10.6%) had an observed adverse reaction compared to 3/42 (7.1%) who had an observed reaction with a reported high-risk or anaphylactic allergy.Conclusions:Our implemented protocol was safe and effective, with over 90% of patients tolerating the challenge without incident and many going on to receive indicated beta-lactam therapy. This protocol may serve as a framework for other inpatient ASP teams to implement a low-barrier allergy assessment led by ASP teams.


  • Open Access

    Acute Respiratory Distress Syndrome and the Use of Inhaled Pulmonary Vasodilators in the COVID-19 Era: A Narrative Review

    by Adeel Nasrullah, Shiza Virk, Aaisha Shah, Max Jacobs, Amina Hamza, Abu Baker Sheikh, Anam Javed, Muhammad Ali Butt, Swathi Sangli

    The Coronavirus disease (COVID-19) pandemic of 2019 has resulted in significant morbidity and mortality, especially from severe acute respiratory distress syndrome (ARDS). As of September 2022, more than 6.5 million patients have died globally, and up to 5% required intensive care unit treatment. COVID-19-associated ARDS (CARDS) differs from the typical ARDS due to distinct pathology involving the pulmonary vasculature endothelium, resulting in diffuse thrombi in the pulmonary circulation and impaired gas exchange. The National Institute of Health and the Society of Critical Care Medicine recommend lung-protective ventilation, prone ventilation, and neuromuscular blockade as needed. Further, a trial of pulmonary vasodilators is suggested for those who develop refractory hypoxemia. A review of the prior literature on inhaled pulmonary vasodilators in ARDS suggests only a transient improvement in oxygenation, with no mortality benefit. This narrative review aims to highlight the fundamental principles in ARDS management, delineate the fundamental differences between CARDS and ARDS, and describe the comprehensive use of inhaled pulmonary vasodilators. In addition, with the differing pathophysiology of CARDS from the typical ARDS, we sought to evaluate the current evidence regarding the use of inhaled pulmonary vasodilators in CARDS.


  • Impact of Convalescent Plasma Therapy in Hospitalized Patients With Severe COVID-19

    by Thomas L. Walsh, Nathan R. Shively, Dustin R. Carr, Derek N. Bremmer, Chas Hoffmann, Max W. Do Jacobs, Linda Santelices, Michael Ma Anderson, Sarah Bs Rutman, Nicole Bs Wilson, et al.

    Background Convalescent plasma (CP) is often administered to hospitalized patients with COVID-19, but the impact on clinical outcomes has varied across different patient populations. Methods A retrospective, propensity score–matched controlled study was conducted to compare outcomes of hospitalized patients with nonmechanically ventilated severe COVID-19 who received CP within 36 hours of hospital admission with those who did not receive CP during their hospitalization. A combination of propensity score matching and Mahalanobis distance matching was used. Results One hundred forty-three patients were originally in the treatment group, and 94 were able to be matched to control patients who did not receive CP during their hospital stay. Receipt of early CP was not associated with significant differences in clinical outcomes. Overall 30-day mortality was 12.8% in the CP group and 14.9% in the non-CP group (P = 0.67). No significant differences were observed between the early CP group and the non-CP group for 30-day readmissions (12.8% vs 9.6%; P = 0.47), subsequent transfer to an intensive care unit (2.1% vs 2.1%; P = 1.0), and subsequent progression to noninvasive ventilation after 36 hours from admission (12.8% vs 5.3%; P = 0.07). Receipt of early CP was associated with increased need for mechanical ventilation after 36 hours from admission (12.8% vs 3.2%; P = 0.013). Conclusions Receipt of early CP for hospitalized patients with severe COVID-19 but not requiring mechanical ventilation was not associated with improvements in clinical status or mortality compared with matched patients who did not receive CP.